TargetMol

Otenaproxesul

Product Code:
 
TAR-T1867
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1867-2mg2mg£98.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1867-5mg5mg£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1867-1mL1 mL * 10 mM (in DMSO)£119.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1867-10mg10mg£142.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1867-25mg25mg£213.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1867-50mg50mg£303.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1867-100mg100mg£442.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1867-500mg500mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
ATB-346 is a novel hydrogen sulphide-releasing derivative of naproxen with markedly reduced toxicity.
CAS:
1226895-20-0
Formula:
C21H19NO3S
Molecular Weight:
365.45
Pathway:
Immunology/Inflammation; Apoptosis; Neuroscience
Purity:
0.9923
SMILES:
COc1ccc2cc(ccc2c1)C(C)C(=O)Oc1ccc(cc1)C(N)=S
Target:
Apoptosis; COX

References

1. Wallace JL, et al. Br J Pharmacol. 2010 Mar;159(6):1236-46.